MX2022010800A - Composiciones y metodos para la administracion de naloxona. - Google Patents

Composiciones y metodos para la administracion de naloxona.

Info

Publication number
MX2022010800A
MX2022010800A MX2022010800A MX2022010800A MX2022010800A MX 2022010800 A MX2022010800 A MX 2022010800A MX 2022010800 A MX2022010800 A MX 2022010800A MX 2022010800 A MX2022010800 A MX 2022010800A MX 2022010800 A MX2022010800 A MX 2022010800A
Authority
MX
Mexico
Prior art keywords
naloxone
compositions
methods
delivery
treatment
Prior art date
Application number
MX2022010800A
Other languages
English (en)
Inventor
Haiyong Hugh Huang
Manjunath S Shet
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of MX2022010800A publication Critical patent/MX2022010800A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En ciertas modalidades se describe una formulación que comprende una cantidad con eficacia terapéutica de naloxona o una sal farmacéuticamente aceptable de esta y un adyuvante que potencia la absorción de la naloxona en la circulación sistémica de un sujeto. También se describen en la presente un método de tratamiento y un kit que se puede utilizar en el tratamiento.
MX2022010800A 2020-03-11 2021-02-26 Composiciones y metodos para la administracion de naloxona. MX2022010800A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062988161P 2020-03-11 2020-03-11
PCT/US2021/019902 WO2021183303A1 (en) 2020-03-11 2021-02-26 Compositions and methods for naloxone delivery

Publications (1)

Publication Number Publication Date
MX2022010800A true MX2022010800A (es) 2022-09-27

Family

ID=77671924

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010800A MX2022010800A (es) 2020-03-11 2021-02-26 Composiciones y metodos para la administracion de naloxona.

Country Status (6)

Country Link
US (1) US20230095235A1 (es)
EP (1) EP4117629A4 (es)
BR (1) BR112022017433A2 (es)
CA (1) CA3171263A1 (es)
MX (1) MX2022010800A (es)
WO (1) WO2021183303A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001026642A2 (en) * 1999-10-08 2001-04-19 Joyce Corinne Bechthold Methods and compositions for treating neurobehavioral disorders
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
AU2012311293B2 (en) * 2011-09-19 2014-02-20 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
WO2016007729A1 (en) * 2014-07-09 2016-01-14 Lightlake Therapeutics Inc. Co-packaged drug products
EP3237388B1 (en) * 2014-12-23 2019-07-03 Nektar Therapeutics N-methyl-n-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-2-aminophenylacetamide derivatives agonists for the kappa opioid receptor
US20180177777A1 (en) * 2016-12-28 2018-06-28 Michael Ballek Formulations for mitigating opioid overdose and methods of making and using the same
US20210228570A1 (en) * 2018-06-01 2021-07-29 Purdue Pharma L.P. Compositions and methods for opioid overdose rescue
WO2020097279A1 (en) * 2018-11-07 2020-05-14 Opiant Pharmaceuticals, Inc. Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose

Also Published As

Publication number Publication date
WO2021183303A1 (en) 2021-09-16
BR112022017433A2 (pt) 2022-10-18
EP4117629A1 (en) 2023-01-18
US20230095235A1 (en) 2023-03-30
CA3171263A1 (en) 2021-09-16
EP4117629A4 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
EP4327882A3 (en) Enpp1 inhibitors and their use for the treatment of cancer
MX2021002886A (es) Terapia de combinacion para el tratamiento de cancer de mama triple negativo.
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
HRP20050633A2 (en) Formulation and methods for the treatment of thrombocythemia
PH12021550537A1 (en) Oral formulations of kappa opioid receptor agonists
MX2020005621A (es) Derivados de acidos grasos para tratar la esteatohepatitis no alcoholica.
MX2021013582A (es) Composiciones que comprenden agentes biologicamente activos y sales biliares.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2022010800A (es) Composiciones y metodos para la administracion de naloxona.
NO20023102L (no) Fremgangsmåte og formulering for behandling av residens mot anti-hypertensiver og relaterte tilstander
MX2020007066A (es) Reduccion de la expresion de beta-catenina e ido para potenciar la inmunoterapia.
MX2023007080A (es) Metodo para el tratamiento de la fibrosis.
PL372096A1 (en) Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
WO2022020114A3 (en) Methods for the prevention and treatment of hearing loss
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2022007009A (es) Composicion topica y metodos de medicion de la capacidad de refrigeracion de una composicion.
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
MX2013014518A (es) Composiciones y metodos para tratar, controlar, reducir, o mejorar el dolor inflamatorio.
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
WO2020160493A3 (en) Compounds, compositions and methods for treatment of myopia
MX2021005905A (es) Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.